Jordi Rodon

2 weeks ago | nature.com | Ying Cheng |Jun Liao |Jordi Rodon |Yongsheng Li |Yun Fan |Jin Billy Li | +1 more

AbstractTrophoblast cell-surface antigen 2 (TROP2)-directed antibody–drug conjugate (ADC) is a promising anticancer agent that has shown remarkable efficacy in several malignancies. However, in lung cancer, two phase 3 trials on TROP2-ADCs in unselected patients with advanced non-small-cell lung cancer (NSCLC) have both failed. Sacituzumab tirumotecan (sac-TMT) is a novel TROP2-directed ADC.

May 24, 2024 | nature.com | Jordi Rodon |Silvia Damian |Jesús García-Donas |Antoine Italiano |Iben Spanggaard |Tomoya Yokota | +1 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-02934-7, published online 6 May 2024In the version of the article initially published, patient numbers and ratios of the trial cohorts were missing from the abstract and have now been added in the HTML and PDF versions of the article.

May 6, 2024 | nature.com | Jordi Rodon |Silvia Damian |Jesús García-Donas |Antoine Italiano |Iben Spanggaard |Tomoya Yokota | +1 more

AbstractFibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1–FGFR3 inhibitor, in the phase 2 FIGHT-207 basket study of FGFR-altered advanced solid tumors. Primary end points were objective response rate (ORR) in cohorts A (fusions/rearrangements) and B (activating non-kinase domain mutations).

Mar 20, 2024 | nature.com | Marco Brustolin |Nuria Pedreno-Lopez |Jordi Rodon |Víctor Urrea |Edwards Pradenas |Anna Pons-Grífols | +10 more

AbstractSafe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels.